Unilens Vision Inc (UVIC) 12.7700 $UVIC
Unilens Vision Inc. Declares Quarterly Cash Dividend Of $0.045 Per Share
PR Newswire - Mon Aug 03, 10:14AM CDT
The Unilens Vision Inc. (OTC Markets Group OTCQX: UVIC) Board of Directors today declared the 36th consecutive quarterly cash dividend, payable August 24, 2015 at $0.045 per common share to stockholders of record at the close of business on August 14, 2015.
WeissLaw LLP: Unilens Vision, Inc. Acquisition By Valeant Pharmaceuticals International, Inc. May Not Be In The Best Interest Of UVIC Shareholders
PR Newswire - Wed Jul 22, 2:06PM CDT
The fairness of the proposed acquisition of Unilens Vision, Inc. ("UVIC" or the "Company"
by Valeant Pharmaceuticals International, Inc. ("Valeant" is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of UVIC for agreeing to sell the Company to Valeant. On July 13, 2015, the Company announced it had reached a definitive agreement for Valeant to acquire UVIC in a transaction valued at approximately $28 million. Under the terms of the agreement, UVIC shareholders will receive $12.75 in cash for each UVIC share they own.
VRX.TO: 31.47 (-5.53)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Unilens Vision Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jul 20, 1:24PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Unilens Vision Inc. ("Unilens" or the "Company" (Other OTC: UVIC) relating to the proposed buyout of the Company by Valeant Pharmaceuticals International, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Unilens Vision Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International
BusinessWire - Thu Jul 16, 12:45PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX.TO: 31.47 (-5.53)
UNILENS VISION INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Valeant Pharmaceuticals International, Inc.
BusinessWire - Wed Jul 15, 12:08PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Unilens Vision Inc. ("Unilens" (OTCQX: UVIC) concerning the sale to Valeant Pharmaceuticals International, Inc. Under the terms of the agreement, Unilens shareholders will only receive $12.75 in cash for each share owned.
VRX.TO: 31.47 (-5.53)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Unilens Vision Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International-- UVIC
PR Newswire - Wed Jul 15, 11:56AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX.TO: 31.47 (-5.53)
UNILENS VISION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Unilens Vision Inc.
PR Newswire - Tue Jul 14, 5:42PM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF" are investigating the proposed sale of Unilens Vision Inc. ("Unilens" or the "Company" (OTCQX: UVIC) to Valeant Pharmaceuticals International, Inc. (NYSE: VRX). Under the terms of the proposed transaction, shareholders of Unilens will receive only $12.75 in cash for each share of Unilens that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
VRX: 24.64 (-4.21), VRX.TO: 31.47 (-5.53)
Unilens Vision Inc. Signs A Definitive Agreement To Be Acquired By Valeant Pharmaceuticals
PR Newswire - Mon Jul 13, 8:00AM CDT
Unilens Vision Inc. (OTCQX: UVIC) announced today that they have entered into a definitive agreement under which a subsidiary of Valeant Pharmaceuticals International, will acquire all of the outstanding common stock of Unilens Vision Inc. (Unilens) for $12.75 per share in cash, or a total enterprise value of approximately $28 million, which includes approximately $5 million in debt. The transaction was unanimously approved by Unilens' Board of Directors and is expected to close by September 1, 2015, subject to stockholder approval and customary closing conditions. Unilens anticipates holding a special meeting of its stockholders to consider and adopt the Agreement and Plan of Merger in the second half of August 2015.
VRX.TO: 31.47 (-5.53)
Unilens Vision Inc. Named to 2015 OTCQX Best 50
Marketwired - Mon May 18, 11:52AM CDT
Unilens Vision, Inc. (OTCQX: UVIC) is pleased to announce that it has been named to the 2015 OTCQX(R) Best 50, a ranking of 50 top-performing companies traded on the OTCQX Best Marketplace last year.
Unilens Vision Reports Third Quarter Operating Results
Marketwired - Thu May 14, 3:05PM CDT
Unilens Vision Inc. (OTCQX: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported operating results for the third quarter and first nine months of FY2015.
OTC Markets Group Announces OTCQX Best 50
PR Newswire - Wed May 13, 5:59AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities, today announced the 2015 OTCQX® Best 50, the first ever ranking of top performing companies on the OTCQX marketplace.
Unilens Vision Reports Higher Sales, Royalty Income, and Earnings for Second Quarter of FY2015
Marketwired - Thu Feb 12, 3:15PM CST
Unilens Vision Inc. (OTCQX: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported operating results for the second quarter and first half of FY2015.
Unilens Vision Inc. Declares Quarterly Cash Dividend Of $0.045 Per Share
PR Newswire - Mon Aug 03, 10:14AM CDT
The Unilens Vision Inc. (OTC Markets Group OTCQX: UVIC) Board of Directors today declared the 36th consecutive quarterly cash dividend, payable August 24, 2015 at $0.045 per common share to stockholders of record at the close of business on August 14, 2015.
WeissLaw LLP: Unilens Vision, Inc. Acquisition By Valeant Pharmaceuticals International, Inc. May Not Be In The Best Interest Of UVIC Shareholders
PR Newswire - Wed Jul 22, 2:06PM CDT
The fairness of the proposed acquisition of Unilens Vision, Inc. ("UVIC" or the "Company"
by Valeant Pharmaceuticals International, Inc. ("Valeant" is the subject of an investigation by WeissLaw LLP, a national class action, shareholder rights law firm. The investigation is focusing on possible breaches of fiduciary duty and other violations of law by the Board of Directors of UVIC for agreeing to sell the Company to Valeant. On July 13, 2015, the Company announced it had reached a definitive agreement for Valeant to acquire UVIC in a transaction valued at approximately $28 million. Under the terms of the agreement, UVIC shareholders will receive $12.75 in cash for each UVIC share they own. VRX.TO: 31.47 (-5.53)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Unilens Vision Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Mon Jul 20, 1:24PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Unilens Vision Inc. ("Unilens" or the "Company"
(Other OTC: UVIC) relating to the proposed buyout of the Company by Valeant Pharmaceuticals International, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Unilens Vision Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International
BusinessWire - Thu Jul 16, 12:45PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX.TO: 31.47 (-5.53)
UNILENS VISION INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Valeant Pharmaceuticals International, Inc.
BusinessWire - Wed Jul 15, 12:08PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Unilens Vision Inc. ("Unilens"
(OTCQX: UVIC) concerning the sale to Valeant Pharmaceuticals International, Inc. Under the terms of the agreement, Unilens shareholders will only receive $12.75 in cash for each share owned. VRX.TO: 31.47 (-5.53)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Unilens Vision Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International-- UVIC
PR Newswire - Wed Jul 15, 11:56AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX.TO: 31.47 (-5.53)
UNILENS VISION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Unilens Vision Inc.
PR Newswire - Tue Jul 14, 5:42PM CDT
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF"
are investigating the proposed sale of Unilens Vision Inc. ("Unilens" or the "Company" (OTCQX: UVIC) to Valeant Pharmaceuticals International, Inc. (NYSE: VRX). Under the terms of the proposed transaction, shareholders of Unilens will receive only $12.75 in cash for each share of Unilens that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. VRX: 24.64 (-4.21), VRX.TO: 31.47 (-5.53)
Unilens Vision Inc. Signs A Definitive Agreement To Be Acquired By Valeant Pharmaceuticals
PR Newswire - Mon Jul 13, 8:00AM CDT
Unilens Vision Inc. (OTCQX: UVIC) announced today that they have entered into a definitive agreement under which a subsidiary of Valeant Pharmaceuticals International, will acquire all of the outstanding common stock of Unilens Vision Inc. (Unilens) for $12.75 per share in cash, or a total enterprise value of approximately $28 million, which includes approximately $5 million in debt. The transaction was unanimously approved by Unilens' Board of Directors and is expected to close by September 1, 2015, subject to stockholder approval and customary closing conditions. Unilens anticipates holding a special meeting of its stockholders to consider and adopt the Agreement and Plan of Merger in the second half of August 2015.
VRX.TO: 31.47 (-5.53)
Unilens Vision Inc. Named to 2015 OTCQX Best 50
Marketwired - Mon May 18, 11:52AM CDT
Unilens Vision, Inc. (OTCQX: UVIC) is pleased to announce that it has been named to the 2015 OTCQX(R) Best 50, a ranking of 50 top-performing companies traded on the OTCQX Best Marketplace last year.
Unilens Vision Reports Third Quarter Operating Results
Marketwired - Thu May 14, 3:05PM CDT
Unilens Vision Inc. (OTCQX: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported operating results for the third quarter and first nine months of FY2015.
OTC Markets Group Announces OTCQX Best 50
PR Newswire - Wed May 13, 5:59AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities, today announced the 2015 OTCQX® Best 50, the first ever ranking of top performing companies on the OTCQX marketplace.
Unilens Vision Reports Higher Sales, Royalty Income, and Earnings for Second Quarter of FY2015
Marketwired - Thu Feb 12, 3:15PM CST
Unilens Vision Inc. (OTCQX: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported operating results for the second quarter and first half of FY2015.
